Fortis Healthcare Modifies NCD Terms

Fortis Healthcare has announced significant changes to the terms of its non-convertible debentures (NCDs). This move comes as part of the company's ongoing efforts to optimize its financial structure and improve its debt profile.

Key Changes

• The company has altered the terms of its NCDs, which are a form of debt instrument.
• These modifications are expected to impact the company's financial obligations and potentially its cash flow.

Implications for Investors

• Investors holding these NCDs may see changes in their expected returns or the timeline of these investments.
• The market will likely closely watch how these changes affect Fortis Healthcare's overall financial health and performance.

Company's Perspective

While specific details of the changes have not been provided, such modifications to debt instruments are often undertaken to:

• Improve the company's debt-to-equity ratio
• Extend maturity dates
• Adjust interest rates
• Enhance overall financial flexibility

Market Response

Investors and market analysts will be keenly observing how these changes impact Fortis Healthcare's stock performance and credit ratings in the coming days.

Conclusion

This development underscores the dynamic nature of corporate finance and the ongoing efforts of companies like Fortis Healthcare to manage their financial obligations effectively. Stakeholders are advised to stay tuned for more detailed information from the company regarding these changes.

Fortis Healthcare Limited , one of India's leading healthcare providers, has reported robust financial results for the second quarter of fiscal year 2026, with significant growth in both revenue and profitability.

Strong Revenue Growth

The company's consolidated revenue for Q2 FY26 stood at INR2,331.00 crores, marking a 17.3% increase compared to the same period last year. This growth was primarily driven by the hospital segment, which saw a 19.3% year-on-year increase in revenue to INR1,974.00 crores. The diagnostic business also contributed positively, with a 7.1% growth in net revenue to INR357.00 crores.

Improved Profitability

Fortis Healthcare's consolidated operating EBITDA surged by 28% to INR556.00 crores, with the EBITDA margin expanding to 23.9% from 21.9% in Q2 FY25. The hospital business reported an operating EBITDA of INR452.00 crores, showing a 150 basis points improvement in margin to 22.9%. The company's profit after tax before exceptional items increased by 20.7% to INR305.00 crores.

Key Operational Metrics

Expansion and Strategic Initiatives

Fortis Healthcare has been actively pursuing growth opportunities:

• Entered a 15-year lease agreement for a 200-bed multi-specialty hospital in Greater Noida.
• Signed an O&M agreement for a 550-bed greenfield super specialty hospital in Lucknow.
• Acquired Shrimann Super Speciality Hospital in Jalandhar, adding 190 operational beds.
• Entered into an O&M agreement with Gleneagles India to manage five hospitals and a clinic.
• Added 550 operational beds in H1 FY26 through various initiatives.

Diagnostic Business Performance

The diagnostic arm, Agilus Diagnostics, reported a 7.3% increase in gross revenue to INR400.00 crores. The operating EBITDA margin for this segment improved to 26.1% from 21.5% in Q2 FY25.

Dr. Ashutosh Raghuvanshi, Managing Director and CEO of Fortis Healthcare, commented on the results: "We continue to witness a healthy growth momentum in Q2 FY26 and H1 of FY26. Both our business segments, Hospitals and Diagnostics, continue to perform well both in terms of revenue and margins."

With these positive results and ongoing expansion initiatives, Fortis Healthcare continues to strengthen its position in the Indian healthcare sector, focusing on both organic growth and strategic acquisitions to enhance its service offerings and market presence.